 |
|
|
| |
10th European AIDS Conference (EACS)
Dublin, Ireland
Nov 17-20, 2005
|
| |
| |
- Tipranavir Response by HCV/HBV Coinfected (12/29/05)
- Second-Line and Salvage Strategies,
(Good News and Bad With TMC125),
When to change a failing regimen,
Kaletra & Fosamprenavir/r for PI Resistance,
How efavirenz affects new lopinavir tablet,
Lopinavir/ritonavir inhibits CYP2D6,
Omeprazole hoists saquinavir levels,
Antiretroviral switch = failure, or not? Mark Mascolini (12/27/05)
- Tipranavir response in RESIST Stratified by Previous PI Use, & Baseline Viral Load & CD4 Count (12/06/05)
- Tipranavir Response by HCV/HBV Coinfected (12/06/05)
- FTC Had Less M184 than 3TC (12/02/05)
- Pretreatment Questions and First-Line Options written for NATAP by Mark Mascolini (12/02/05)
- FTC Had Less M184 than 3TC (12/01/05)
- Resistance in EFV/TDF/FTC Study 934 (12/01/05)
- Lipoatrophy Improved: RAVE Study (12/01/05)
- Tenofovir/3TC/EFV 4 Yr Followup: limb fat, bones, efficacy (12/01/05)
- The Pharmacokinetic Interaction Between Fosamprenavir/Ritonavir and Atazanavir in Healthy Adult Subjects (APV10018) (12/01/05)
- Heart Disease and Mortality Trends in People With HIV Written for NATAP by Mark Mascolini (11/30/05)
- Antiretrovirals and other stuff! Reported by Mike Youle, MD, Royal Free HIV Clinic, London, UK (11/29/05)
- Switch to Unboosted Reyataz (11/29/05)
- Seven Year Follow-up of a Lopinavir/ritonavir (LPV/r)-Based Regimen in Antiretroviral (ARV)-Naive Subjects (11/28/05)
- Tipranavir 48 weeks (RESIST Studies): efficacy & safety (11/28/05)
- Boehringer Ingelheim Announces 48-Week Results from Aptivus(Rtv) (tipranavir) RESIST Studies (11/28/05)
- A Look at Lipoatrophy Predictors and Reversers Written for NATAP by Mark Mascolini (11/28/05)
- Is Liver Toxicity a CCR5 Antagonist Class Effect? 2NN & Hepatoxicity; D.A.D. study & liver related death; Liver toxicity & HIV, Italian study Written for NATAP by Mark Mascolini (11/28/05)
- TMC-125: efficacy & safety in highly resistant patients (11/18/05)
- MK-0518, the first Integrase Inhibitor for HIV, No Blarney (11/18/05)
- TMC-125, new NNRTI for Resistance (11/18/05)
- Preliminary 24-Week Data Evaluating the Impact of Switching from Twice-Daily Combivir(R) to Once-Daily Truvada(R) in Patients with HIV Presented at 10th European AIDS Conference (11/18/05)
|
|
| |
|
|
|
|
|
|
